Oct. 27 - What an NIH study says about COVID-19 antibody drugs | EQRx plan to take on pricey cancer drugs takes shape

EQRx builds cancer drug pipeline as plans to challenge big pharma take shape; Exact Sciences, challenging Illumina, to buy cancer screening company Thrive; Record numbers of biotechs are going public. Here's how they're performing. View online | Signup | Forward

Daily Dive Oct.​ 27,​ 2020 | Today's news and insights for biopharma leaders   BROUGHT TO YOU BY — PQE Group Innovate your quality, with PQE Group Choose our smart solutions to enhance data integrity. Request demo.   UPDATED Lilly antibody drug doesn't help hospitalized COVID-19 patients in NIH study The results could raise doubts about the ability of synthetic antibody drugs to help patients already very sick with COVID-19. EQRx builds cancer drug pipeline as plans to challenge big pharma take shape The startup, which aims to develop lower-cost alternatives to branded medicines, has licensed two drugs from CStone Pharmaceuticals in a deal that could signal a coming price war in cancer immunotherapy. UPDATED Exact Sciences, challenging Illumina, to buy cancer screening company Thrive The deal, worth up to $2.15 billion, comes weeks after Illumina agreed to pay $8 billion to acquire liquid biopsy developer Grail. Sponsored Content by Parexel International Identifying and recruiting patients into rare disease clinical trials: A multi-pronged and customized approach Learn how to give people with a rare disease the opportunity to participate in a study. Record numbers of biotechs are going public. Here's how they're performing. Initial public offerings have fueled biotech's boom. A new database built by BioPharma Dive will help you keep track of them as they happen.  Read more news Featured Resources FROM: WCG Getting medicines and care with the speed we need while keeping patients safe during COVID-19 It's All About the Trust: Authentic Community Engagement Key to Diverse Trial Enrollment Advocating for Patients in a Time of COVID-19 There is Value to Patients When Independent Sites Offer Clinical Trials From Our Library Trendline Inside the Rapidly Changing World of Gene Therapy Trendline Trends and Developments in Real-World Evidence View all resources What We're Reading POLITICO Medicare and Medicaid to cover early Covid vaccine The Boston Globe Scorpion, seeking to develop 'precision medicine' drugs for cancer, debuts with $108m in funding Kaiser Health News Florida Fails to Attract Bidders for Canada Drug Importation Program STAT Covid-19 expert Akiko Iwasaki fights a different virus: sexism in science Suggest a story we should read Company Announcements Press releases from companies in your industry. Saama Launches Active Safety Analytics for Pharma (ASAP), Co-built with Gilead to Transform Safety Surveillance Press release from Saama Technologies BioIVT to Host Emerging Technologies in Diagnostics Symposium Press release from BioIVT Post a press release Dive Into a Topic Pharma Biotech FDA Clinical Trials Deals Drug Pricing Gene Therapy Share BioPharma Dive: Daily Dive with others and get rewarded. You've referred 0 readers. To become an official Dive Insider, just successfully refer 10 contacts to BioPharma Dive: Daily Dive. Here's your link to share: https://www.biopharmadive.com/signup/insiders/?signup_referred_by=5f93078d7aa51972095c9316

More Than A Newsletter Related Publications Healthcare Dive | MedTech Dive Connect With Us Twitter | Facebook | LinkedIn Editorial Contact an editor | Meet the team Advertising Contact our team About BioPharma Dive BioPharma Dive provides in-depth journalism and insight into the most impactful news and trends shaping biotech and pharma. The newsletter and website cover topics ranging from clinical readouts to FDA approvals, gene therapy to drug pricing and M&A to research partnerships. BioPharma Dive is a leading industry publication operated by Industry Dive. Our business journalists spark ideas and shape agendas for 10+ million decision makers in the most competitive industries. Sign up for the newsletter This email is optimized for display on mobile phones. BioPharma Dive: Daily Dive is a product of Industry Dive, Inc.. 1575​ Eye St NW, 4th Floor, Washington,​ DC 20005. We value your privacy. We won't share your email address with anyone else without your permission. This message was sent to edwardlorilla1986.acciyo123@blogger.com. You can unsubscribe or switch to a weekly newsletter subscription anytime. See our full privacy policy.

Sign up | Manage subscription | Advertise with us | Submit story tip